© 2007 The Royal College of Psychiatrists
Correspondence |
Depression post-myocardial infarction
Wolfson Institute of Preventive Medicine, Barts and the London, Queen Mary’s School of Medicine and Dentistry, London, UK. Email: a.korszun{at}qmul.ac.uk
Wolfson Institute of Preventive Medicine, Barts and the London, Queen Mary’s School of Medicine and Dentistry, London, UK
EDITED BY KIRIAKOS XENITIDIS and COLIN CAMPBELL
Van Melle et al (2007) reported that cardiac prognosis post-myocardial infarction was not improved by antidepressant treatment (MIND–IT trial). The SADHART and ENRICHD trials reported similar findings and Carney & Freedland (2007), in their commentary in the same issue, suggest these negative findings are a result of insufficient statistical power in the trials. These results are disappointing but perhaps they might have been anticipated.
There is strong evidence that individuals with depression show increased morbidity and mortality from coronary heart disease (Rugulies, 2002) but the mechanisms involved remain unclear. Individuals with a history of recurrent depression, who are otherwise healthy, show increased inflammation, platelet activation, endothelial dysfunction, and reduced heart rate variability and baroreceptor sensitivity. However, with the exception of platelet function, which improves with selective serotonin reuptake inhibitors, these anomalies are not corrected by antidepressant treatment. Furthermore, endothelial function and baroreceptor sensitivity, which can lead respectively to progression of the atherosclerotic process and to sudden cardiac death, do not improve when depressive symptoms are in remission (Broadley et al, 2006). Thus there is no evidence that treatment of depressive symptoms post-myocardial infarction corrects these underlying pathological processes and, if it does not, cardiac outcomes disclosed by clinical trials are unlikely to show improvement irrespective of their statistical power. By analogy, although hyperglycaemia characterises diabetes, tight glucose control alone has only a modest impact on cardiovascular events. Similarly, depressive illness is characterised by acute episodes of depression, but other systemic abnormalities are present and persist between acute depressive episodes. Accordingly, it may be unreasonable to believe that treatments assessed by their influence on the affective state alone will reduce cardiovascular events.
Although it is important to alleviate the suffering associated with developing depression post-myocardial infarction and improve prognosis by addressing the secondary effects of depression (e.g. reduced adherence to treatment and poor health behaviours), treatment needs to be aimed at earlier stages of the disorder. Atherosclerosis begins in childhood and becomes manifest much later in life, with myocardial infarction as a very late presentation. Similarly, depression is a lifelong disorder with onset in early adulthood. It should be noted that currently depression is not even included in cardiovascular risk tables and that individuals with depression might benefit from introduction of statins, or other preventative measures.
We agree with Carney & Freedland (2007) that treatments for depression might alter the risk of cardiac events via pathways that are unrelated to their effects on depression. However, if the focus of research were shifted to the study of earlier stages of coronary heart disease in people with depression, this could be clarified by monitoring earlier indices of heart disease in relation to treatment of depression. It is also recognised that mechanisms for associations between depression and onset of heart disease may differ from those between depression and progression of coronary heart disease post-myocardial infarction. These pathways need to be better understood and present evidence suggests that survival times following myocardial infarction could be improved by developing treatments for depression that also target the underlying cardiovascular abnormalities and by augmenting these by preventative programmes for coronary heart disease in individuals with mood disorders.
Coronary heart disease and depression are two major public health problems and it is of concern that reports of treatments for depression failing to enhance survival post-myocardial infarction may result in less interest in studying the links between them.
REFERENCES
- Broadley, A. J., Korszun, A., Abdelaal, E., et al
(2006) Metyrapone improves endothelial dysfunction in
patients with treated depression. Journal of the American College
of Cardiology, 48, 170
–175.
[Abstract/Free Full Text] - Carney, R. M. & Freedland, K. E. (2007)
Does treating depression improve survival after acute coronary syndrome?
British Journal of Psychiatry,
190, 467
–468.
[Abstract/Free Full Text] - Rugulies, R. (2002) Depression as a predictor for coronary heart disease: a review and meta-analysis. American Journal of Preventive Medicine, 23, 51 –61.[CrossRef][Medline]
- Van Melle, J. P., de Jonge, P., Honig, A., et al
(2007) Effects of antidepressant treatment following
myocardial infarction. British Journal of Psychiatry,
190, 460
–466.
[Abstract/Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  J. Seymour and T. B. Benning Depression, cardiac mortality and all-cause mortality Adv. Psychiatr. Treat., March 1, 2009; 15(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||